Infectious complications of acute and chronic liver disease

Seminars in Respiratory and Critical Care Medicine

Volumn 33, Issue 1, 2012, Pages 80-95

  Leber, Bettina ^a   Spindelboeck, Walter ^a   Stadlbauer, Vanessa ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

acute liver failure; immune dysfunction; infection; liver cirrhosis

Indexed keywords

ALBUMIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTIVIRUS AGENT; CEPHALOSPORIN; ERITORAN; HEPATITIS VACCINE; HIGH DENSITY LIPOPROTEIN; HUMAN SERUM ALBUMIN; NORFLOXACIN; OMEGA 3 FATTY ACID; PROBIOTIC AGENT; RESATORVID; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LIVER FAILURE; ACUTE ON CHRONIC LIVER FAILURE; ANTIBIOTIC PROPHYLAXIS; ASCITES; BACTEREMIA; BACTERIAL CLEARANCE; BACTERIAL INFECTION; BACTERIAL PERITONITIS; BARIATRIC SURGERY; BODY MASS; CHOLANGITIS; CHRONIC LIVER DISEASE; CHRONIC LIVER FAILURE; DISEASE ASSOCIATION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; ENDOTOXEMIA; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; HEPATIC ENCEPHALOPATHY; HEPATITIS A; HEPATITIS B; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INNATE IMMUNITY; INTENSIVE CARE UNIT; INVASIVE ASPERGILLOSIS; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT; LIVER SUPPORT; LIVER TRANSPLANTATION; MALNUTRITION; MONOCYTE; MYCOSIS; NEUTROPHIL; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; SEPSIS; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPPER GASTROINTESTINAL BLEEDING; URINARY TRACT INFECTION; URINE CULTURE; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; END STAGE LIVER DISEASE; FATTY LIVER; HUMANS; LIVER CIRRHOSIS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; LIVER, ARTIFICIAL; PROGNOSIS; SEVERITY OF ILLNESS INDEX;

EID: 84858732611     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0032-1301737     Document Type: Review

References (226)

1. Leon DA, McCambridge J. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet: 2006; 367 9504 52 56 (Pubitemid 43038670)
2. Centers for Disease Control and Prevention. Vital and health statistics, Series 13. Average length of stay in short-stay hospitals: demographic factors: United States, 1968. Gordon EW. April 1973. 46 pp. (HSM) 73-1764. PB88-227038. PC A03 MF A01
3. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol: 2000; 15 5 480 488 (Pubitemid 30327048)
4. Mansour A, Watson W, Shayani V, Pickleman J. Abdominal operations in patients with cirrhosis: still a major surgical challenge. Surgery: 1997; 122 4 730 735, discussion 735-736
5. Garcia-Tsao G. Bacterial infections in cirrhosis. Can J Gastroenterol: 2004; 18 6 405 406 (Pubitemid 39076996)
6. Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC. Predictors of mortality and resource utilization in cirrhotic patients admitted to the medical ICU. Chest: 2001; 119 5 1489 1497 (Pubitemid 32686034)
7. Caly WR, Strauss E. A prospective study of bacterial infections in patients with cirrhosis. J Hepatol: 1993; 18 3 353 358 (Pubitemid 23279724)
8. Navasa M, Fernndez J, Rods J. Bacterial infections in liver cirrhosis. Ital J Gastroenterol Hepatol: 1999; 31 7 616 625 (Pubitemid 29527855)
9. Borzio M, Salerno F, Piantoni L., et al. Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study. Dig Liver Dis: 2001; 33 1 41 48 (Pubitemid 32186174)
10. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol: 2007; 102 7 1510 1517 (Pubitemid 46976304)
11. Fernndez J, Navasa M, Gmez J., et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology: 2002; 35 1 140 148 (Pubitemid 34032554)
12. Navasa M, Rods J. Bacterial infections in cirrhosis. Liver Int: 2004; 24 4 277 280 (Pubitemid 39162066)
13. Rimola A, Garca-Tsao G, Navasa M., et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol: 2000; 32 1 142 153 (Pubitemid 30039459)
14. Conn HO. Spontaneous peritonitis and bacteremia in Laennec's cirrhosis caused by enteric organisms: a relatively common but rarely recognized syndrome. Ann Intern Med: 1964; 60 568 580
15. Arvaniti V, D'Amico G, Fede G., et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology: 2010; 139 4 1246 1256, e1-e5
16. Nobre SR, Cabral JE, Gomes JJ, Leito MC. In-hospital mortality in spontaneous bacterial peritonitis: a new predictive model. Eur J Gastroenterol Hepatol: 2008; 20 12 1176 1181
17. Burroughs AK, Rosenstein IJ, Epstein O, Hamilton-Miller JM, Brumfitt W, Sherlock S. Bacteriuria and primary biliary cirrhosis. Gut: 1984; 25 2 133 137 (Pubitemid 14131405)
18. O'Donohue J, Workman MR, Rolando N, Yates M, Philpott-Howard J, Williams R. Urinary tract infections in primary biliary cirrhosis and other chronic liver diseases. Eur J Clin Microbiol Infect Dis: 1997; 16 10 743 746 (Pubitemid 27496743)
19. Cruz RdeC, Tanajura D, Almeida D, Cruz M, Paran R. Urinary tract infection in non-hospitalized patients with cirrhosis and no symptoms of urinary tract infection: a case series study. Braz J Infect Dis: 2006; 10 6 380 383 (Pubitemid 46585566)
20. Rosa H, Silvrio AO, Perini RF, Arruda CB. Bacterial infection in cirrhotic patients and its relationship with alcohol. Am J Gastroenterol: 2000; 95 5 1290 1293 (Pubitemid 30263526)
21. Viasus D, Garcia-Vidal C, Castellote J., et al. Community-acquired pneumonia in patients with liver cirrhosis: clinical features, outcomes, and usefulness of severity scores. Medicine (Baltimore): 2011; 90 2 110 118
22. Chen SY, Tsai CL, Lin CH., et al. Impact of liver cirrhosis on mortality in patients with community-acquired bacteremia. Diagn Microbiol Infect Dis: 2009; 64 2 124 130
23. Lin JN, Tsai YS, Lai CH., et al. Risk factors for mortality of bacteremic patients in the emergency department. Acad Emerg Med: 2009; 16 8 749 755
24. Linderoth G, Jepsen P, Schnheyder HC, Johnsen SP, Srensen HT. Short-term prognosis of community-acquired bacteremia in patients with liver cirrhosis or alcoholism: a population-based cohort study. Alcohol Clin Exp Res: 2006; 30 4 636 641
25. Koulaouzidis A, Bhat S, Saeed AA. Spontaneous bacterial peritonitis. World J Gastroenterol: 2009; 15 9 1042 1049
26. Cholongitas E, Papatheodoridis GV, Lahanas A, Xanthaki A, Kontou-Kastellanou C, Archimandritis AJ. Increasing frequency of gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int: 2005; 25 1 57 61 (Pubitemid 40298245)
27. Falcone M, Massetti AP, Russo A, Vullo V, Venditti M. Invasive aspergillosis in patients with liver disease. Med Mycol: 2011; 49 4 406 413
28. Mookerjee RP, Stadlbauer V, Lidder S., et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology: 2007; 46 3 831 840 (Pubitemid 47436130)
29. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol: 2006; 44 1 217 231 (Pubitemid 41772537)
30. Kamath PS, Kim WR.; Advanced Liver Disease Study Group. The model for end-stage liver disease (MELD). Hepatology: 2007; 45 3 797 805 (Pubitemid 46450631)
31. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol: 2005; 42 1, Suppl S100 S107 (Pubitemid 40364609)
32. Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis in critically ill patients with cirrhosis assessed by prognostic scoring systems. Hepatology: 2001; 34 2 255 261 (Pubitemid 32702337)
33. Tsai MH, Peng YS, Lien JM., et al. Multiple organ system failure in critically ill cirrhotic patients: a comparison of two multiple organ dysfunction/failure scoring systems. Digestion: 2004; 69 3 190 200
34. Tsai MH, Chen YC, Ho YP., et al. Organ system failure scoring system can predict hospital mortality in critically ill cirrhotic patients. J Clin Gastroenterol: 2003; 37 3 251 257
35. Chen YC, Tsai MH, Hsu CW., et al. Role of serum creatinine and prognostic scoring systems in assessing hospital mortality in critically ill cirrhotic patients with upper gastrointestinal bleeding. J Nephrol: 2003; 16 4 558 565
36. Vincent JL, Moreno R, Takala J., et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med: 1996; 22 7 707 710
37. Zauner CA, Apsner RC, Kranz A., et al. Outcome prediction for patients with cirrhosis of the liver in a medical ICU: a comparison of the APACHE scores and liver-specific scoringsystems. Intensive Care Med: 1996; 22 6 559 563 (Pubitemid 26202598)
38. Zimmermann M, Busch K, Kuhn S, Zeppezauer M. Endotoxin adsorbent based on immobilized human serum albumin. Clin Chem Lab Med: 1999; 37 3 373 379 (Pubitemid 29209755)
39. Singh N, Gayowski T, Wagener MM, Marino IR. Outcome of patients with cirrhosis requiring intensive care unit support: prospective assessment of predictors of mortality. J Gastroenterol: 1998; 33 1 73 79 (Pubitemid 28067778)
40. Kress JP, Rubin A, Pohlman AS, Hall JB. Outcomes of critically ill patients denied consideration for liver transplantation. Am J Respir Crit Care Med: 2000; 162 2 Pt 1 418 423 (Pubitemid 30647176)
41. Afessa B, Kubilis PS. Upper gastrointestinal bleeding in patients with hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol: 2000; 95 2 484 489 (Pubitemid 30106181)
42. Ho YP, Chen YC, Yang C., et al. Outcome prediction for critically ill cirrhotic patients: a comparison of APACHE II and Child-Pugh scoring systems. J Intensive Care Med: 2004; 19 2 105 110 (Pubitemid 44526575)
43. Chen YC, Tsai MH, Ho YP., et al. Comparison of the severity of illness scoring systems for critically ill cirrhotic patients with renal failure. Clin Nephrol: 2004; 61 2 111 118
44. Gildea TR, Cook WC, Nelson DR., et al. Predictors of long-term mortality in patients with cirrhosis of the liver admitted to a medical ICU. Chest: 2004; 126 5 1598 1603 (Pubitemid 39525036)
45. Rabe C, Schmitz V, Paashaus M., et al. Does intubation really equal death in cirrhotic patients? Factors influencing outcome in patients with liver cirrhosis requiring mechanical ventilation. Intensive Care Med: 2004; 30 8 1564 1571 (Pubitemid 39094957)
46. du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The attributable mortality of acute renal failure in critically ill patients with liver cirrhosis. Intensive Care Med: 2005; 31 12 1693 1699 (Pubitemid 41677246)
47. Vitalis Z, Altorjay I, Tornai I., et al. Phenotypic polymorphism of haptoglobin: a novel risk factor for the development of infection in liver cirrhosis. Hum Immunol: 2011; 72 4 348 354
48. Younossi ZM, Stepanova M, Afendy M., et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol: 2011; 9 6 524 530, e1, quiz e60
49. Ribeireiro T, Swain J, Sarr M., et al. NAFLD and insulin resistance do not increase the risk of postoperative complications among patients undergoing bariatric surgerya prospective analysis. Obes Surg: 2011; 21 3 310 315
50. Farhadi A, Gundlapalli S, Shaikh M., et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int: 2008; 28 7 1026 1033 (Pubitemid 352044451)
51. Day CP, James OF. Steatohepatitis: a tale of two "hitso"? Gastroenterology: 1998; 114 4 842 845
52. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A: 1997; 94 6 2557 2562 (Pubitemid 27136914)
53. Polson J, Lee WM.; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology: 2005; 41 5 1179 1197 (Pubitemid 40593928)
54. Schmidt LE, Larsen FS. Prognostic implications of hyperlactatemia, multiple organ failure, and systemic inflammatory response syndrome in patients with acetaminophen-induced acute liver failure. Crit Care Med: 2006; 34 2 337 343 (Pubitemid 43145610)
55. Wade J, Rolando N, Philpott-Howard J, Wendon J. Timing and aetiology of bacterial infections in a liver intensive care unit. J Hosp Infect: 2003; 53 2 144 146 (Pubitemid 38002073)
56. Antoniades CG, Berry PA, Davies ET., et al. Reduced monocyte HLA-DR expression: a novel biomarker of disease severity and outcome in acetaminophen-induced acute liver failure. Hepatology: 2006; 44 1 34 43 (Pubitemid 44049137)
57. Rolando N, Gimson A, Wade J, Philpott-Howard J, Casewell M, Williams R. Prospective controlled trial of selective parenteral and enteral antimicrobial regimen in fulminant liver failure. Hepatology: 1993; 17 2 196 201 (Pubitemid 23046688)
58. Vaquero J, Polson J, Chung C., et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology: 2003; 125 3 755 764 (Pubitemid 37070693)
59. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis: 1996; 16 4 389 402 (Pubitemid 27074781)
60. Canalese J, Gove CD, Gimson AE, Wilkinson SP, Wardle EN, Williams R. Reticuloendothelial system and hepatocytic function in fulminant hepatic failure. Gut: 1982; 23 4 265 269 (Pubitemid 12152740)
61. Wyke RJ, Yousif-Kadaru AG, Rajkovic IA, Eddleston AL, Williams R. Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure. Clin Exp Immunol: 1982; 50 2 442 449 (Pubitemid 12004875)
62. Clapperton M, Rolando N, Sandoval L, Davies E, Williams R. Neutrophil superoxide and hydrogen peroxide production in patients with acute liver failure. Eur J Clin Invest: 1997; 27 2 164 168 (Pubitemid 27101389)
63. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology: 2000; 32 4 Pt 1 734 739
64. Karvellas CJ, Pink F, McPhail M., et al. Predictors of bacteraemia and mortality in patients with acute liver failure. Intensive Care Med: 2009; 35 8 1390 1396
65. Rolando N, Harvey F, Brahm J., et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology: 1990; 11 1 49 53 (Pubitemid 20075101)
66. Cuellar-Rodrguez J, Sierra-Madero JG. [Infections in solid organ transplant recipients]. Rev Invest Clin: 2005; 57 2 368 380 (Pubitemid 41357781)
67. Hollenbeak CS, Alfrey EJ, Souba WW. The effect of surgical site infections on outcomes and resource utilization after liver transplantation. Surgery: 2001; 130 2 388 395 (Pubitemid 32721696)
68. Merli M, Giusto M, Gentili F., et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int: 2010; 30 2 208 214
69. Shi SH, Kong HS, Xu J., et al. Multidrug resistant gram-negative bacilli as predominant bacteremic pathogens in liver transplant recipients. Transpl Infect Dis: 2009; 11 5 405 412
70. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med: 2007; 357 25 2601 2614 (Pubitemid 350294226)
71. Sun HY, Cacciarelli TV, Singh N. Impact of pretransplant infections on clinical outcomes of liver transplant recipients. Liver Transpl: 2010; 16 2 222 228
72. Janny S, Bert F, Dondero F., et al. Microbiological findings of culture-positive preservation fluid in liver transplantation. Transpl Infect Dis: 2011; 13 1 9 14
73. Weiss E, Dahmani S, Bert F., et al. Early-onset pneumonia after liver transplantation: microbiological findings and therapeutic consequences. Liver Transpl: 2010; 16 10 1178 1185
74. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology: 1995; 21 5 1328 1336
75. Singh N, Wagener MM, Obman A, Cacciarelli TV, de Vera ME, Gayowski T. Bacteremias in liver transplant recipients: shift toward gram-negative bacteria as predominant pathogens. Liver Transpl: 2004; 10 7 844 849 (Pubitemid 38979253)
76. Singh N, Avery RK, Munoz P., et al. Trends in risk profiles for and mortality associated with invasive aspergillosis among liver transplant recipients. Clin Infect Dis: 2003; 36 1 46 52 (Pubitemid 36099096)
77. Cockbain AJ, Goldsmith PJ, Gouda M., et al. The impact of postoperative infection on long-term outcomes in liver transplantation. Transplant Proc: 2010; 42 10 4181 4183
78. Aberg F, Mäkisalo H, Höckerstedt K, Isoniemi H. Infectious complications more than 1. year after liver transplantation: a 3-decade nationwide experience. Am J Transplant: 2011; 11 2 287 295
79. Bert F, Galdbart JO, Zarrouk V., et al. Association between nasal carriage of Staphylococcus aureus and infection in liver transplant recipients. Clin Infect Dis: 2000; 31 5 1295 1299 (Pubitemid 32295467)
80. Kawecki D, Chmura A, Pacholczyk M., et al. Etiological agents of bacteremia in the early period after liver transplantation. Transplant Proc: 2007; 39 9 2816 2821 (Pubitemid 350088079)
81. Singh N, Husain S.; AST Infectious Diseases Community of Practice. Invasive aspergillosis in solid organ transplant recipients. Am J Transplant: 2009; 9 Suppl 4 S180 S191
82. Bonham CA, Dominguez EA, Fukui MB., et al. Central nervous system lesions in liver transplant recipients: prospective assessment of indications for biopsy and implications for management. Transplantation: 1998; 66 12 1596 1604 (Pubitemid 29034977)
83. Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol: 2009; 51 3 475 482
84. Thabut D, Massard J, Gangloff A., et al. Model for end-stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure. Hepatology: 2007; 46 6 1872 1882
85. Larcher VF, Wyke RJ, Mowat AP, Williams R. Bacterial and fungal infection in children with fulminant hepatic failure: possible role of opsonisation and complement deficiency. Gut: 1982; 23 12 1037 1043 (Pubitemid 13196629)
86. Leithead JA, Ferguson JW, Bates CM., et al. The systemic inflammatory response syndrome is predictive of renal dysfunction in patients with non-paracetamol-induced acute liver failure. Gut: 2009; 58 3 443 449
87. Miyake Y, Iwasaki Y, Terada R, Takaguchi K, Sakaguchi K, Shiratori Y. Systemic inflammatory response syndrome strongly affects the prognosis of patients with fulminant hepatitis B. J Gastroenterol: 2007; 42 6 485 492 (Pubitemid 47050012)
88. Rayes N, Seehofer D, Hansen S., et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination: a controlled trial in liver transplant recipients. Transplantation: 2002; 74 1 123 127
89. Rayes N, Seehofer D, Theruvath T., et al. Supply of pre- and probiotics reduces bacterial infection rates after liver transplantationa randomized, double-blind trial. Am J Transplant: 2005; 5 1 125 130 (Pubitemid 40095136)
90. Ashare A, Stanford C, Hancock P., et al. Chronic liver disease impairs bacterial clearance in a human model of induced bacteremia. Clin Transl Sci: 2009; 2 3 199 205
91. Hines IN, Wheeler MD. Recent advances in alcoholic liver disease, III: Role of the innate immune response in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol: 2004; 287 2 G310 G314 (Pubitemid 38955249)
92. Jeong WI, Gao B. Innate immunity and alcoholic liver fibrosis. J Gastroenterol Hepatol: 2008; 23 Suppl 1 S112 S118 (Pubitemid 351389022)
93. Thalheimer U, Triantos CK, Samonakis DN, Patch D, Burroughs AK. Infection, coagulation, and variceal bleeding in cirrhosis. Gut: 2005; 54 4 556 563 (Pubitemid 40395508)
94. Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J. Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology: 1984; 4 1 53 58 (Pubitemid 14185424)
95. Ueno M. [Endotoxemia and its compensatory mechanisms in experimental liver cirrhosis]. Nippon Shokakibyo Gakkai Zasshi: 1990; 87 8 1692 1700 (Pubitemid 20297207)
96. Abdala E, Baa CE, Mies S., et al. Bacterial translocation during liver transplantation: a randomized trial comparing conventional with venovenous bypass vs. piggyback methods. Liver Transpl: 2007; 13 4 488 496 (Pubitemid 46613423)
97. von Frankenberg M, Golling M, Mehrabi A, Nentwich H, Klar E, Kraus TW. Donor pretreatment with gadolinium chloride improves early graft function and survival after porcine liver transplantation. Transpl Int: 2003; 16 11 806 813 (Pubitemid 37509417)
98. Ashare A, Monick MM, Powers LS, Yarovinsky T, Hunninghake GW. Severe bacteremia results in a loss of hepatic bacterial clearance. Am J Respir Crit Care Med: 2006; 173 6 644 652 (Pubitemid 43363806)
99. Jaeschke H, Hasegawa T. Role of neutrophils in acute inflammatory liver injury. Liver Int: 2006; 26 8 912 919 (Pubitemid 44323408)
100. Rajkovic IA, Williams R. Mechanisms of abnormalities in host defences against bacterial infection in liver disease. Clin Sci (Lond): 1985; 68 3 247 253 (Pubitemid 15168960)
101. Kirsch R, Woodburne VE, Shephard EG, Kirsch RE. Patients with stable uncomplicated cirrhosis have normal neutrophil function. J Gastroenterol Hepatol: 2000; 15 11 1298 1306
102. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis: 2000; 182 2 526 533 (Pubitemid 30651050)
103. Parlesak A, Schäfer C, Paulus SB, Hammes S, Diedrich JP, Bode C. Phagocytosis and production of reactive oxygen species by peripheral blood phagocytes in patients with different stages of alcohol-induced liver disease: effect of acute exposure to low ethanol concentrations. Alcohol Clin Exp Res: 2003; 27 3 503 508 (Pubitemid 36343296)
104. Garcia-Gonzlez M, Boixeda D, Herrero D, Burgaleta C. Effect of granulocyte-macrophage colony-stimulating factor on leukocyte function in cirrhosis. Gastroenterology: 1993; 105 2 527 531 (Pubitemid 23213541)
105. Taeb J, Mathurin P, Elbim C., et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol: 2000; 32 4 579 586 (Pubitemid 30180377)
106. Stanley AJ, MacGregor IR, Dillon JF, Bouchier IA, Hayes PC. Neutrophil activation in chronic liver disease. Eur J Gastroenterol Hepatol: 1996; 8 2 135 138 (Pubitemid 26130235)
107. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond): 1998; 94 5 461 471 (Pubitemid 28205909)
108. Urbaschek R, McCuskey RS, Rudi V., et al. Endotoxin, endotoxin- neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res: 2001; 25 2 261 268 (Pubitemid 32167443)
109. Etheredge EE, Spitzer JA. Chronic endotoxemia reversibly alters respiratory burst activity of circulating neutrophils. J Surg Res: 1993; 55 3 261 268 (Pubitemid 23346859)
110. Böhmer RH, Trinkle LS, Staneck JL. Dose effects of LPS on neutrophils in a whole blood flow cytometric assay of phagocytosis and oxidative burst. Cytometry: 1992; 13 5 525 531
111. Glauser MP, Zanetti G, Baumgartner JD, Cohen J. Septic shock: pathogenesis. Lancet: 1991; 338 8769 732 736
112. Tsujimoto H, Ono S, Majima T., et al. Neutrophil elastase, MIP-2, and TLR-4 expression during human and experimental sepsis. Shock: 2005; 23 1 39 44 (Pubitemid 40083026)
113. Leber B, Mayrhauser U, Rybczynski M, Stadlbauer V. Innate immune dysfunction in acute and chronic liver disease. Wien Klin Wochenschr: 2009; 121 23-24 732 744
114. Hassner A, Kletter Y, Shlag D, Yedvab M, Aronson M, Shibolet S. Impaired monocyte function in liver cirrhosis. Br Med J (Clin Res Ed): 1981; 282 6272 1262 1263 (Pubitemid 11156860)
115. Xing T, Li L, Cao H, Huang J. Altered immune function of monocytes in different stages of patients with acute on chronic liver failure. Clin Exp Immunol: 2007; 147 1 184 188 (Pubitemid 44915570)
116. Ertel W, Kremer JP, Kenney J., et al. Downregulation of proinflammatory cytokine release in whole blood from septic patients. Blood: 1995; 85 5 1341 1347
117. Guarner-Argente C, Snchez E, Vidal S., et al. Toll-like receptor 4 D299G polymorphism and the incidence of infections in cirrhotic patients. Aliment Pharmacol Ther: 2010; 31 11 1192 1199
118. Nischalke HD, Berger C, Aldenhoff K., et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are associated with increased risk for spontaneous bacterial peritonitis in liver cirrhosis. J Hepatol: 2011; 55 5 1010 1016
119. Ledesma Castao F, Echevarria Vierna S, Lozano Polo JL, Oloriz Rivas R, Alvarez Moreno C, Pons Romero F. Interleukin-1 in alcoholic cirrhosis of the liver: the influence of nutrition. Eur J Clin Nutr: 1992; 46 7 527 533
120. Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med: 1994; 331 17 1122 1128 (Pubitemid 24321217)
121. Ono Y, Watanabe T, Matsumoto K, Ito T, Kunii O, Goldstein E. Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients' blood. J Infect Chemother: 2004; 10 4 200 207 (Pubitemid 39273437)
122. Akalin HE, Laleli Y, Telatar H. Serum bactericidal and opsonic activities in patients with non-alcoholic cirrhosis. Q J Med: 1985; 56 220 431 437 (Pubitemid 16221670)
123. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology: 2005; 41 3 422 433 (Pubitemid 40289486)
124. Petrasek J, Mandrekar P, Szabo G. Toll-like receptors in the pathogenesis of alcoholic liver disease. Gastroenterol Res Pract: 2010; 201
125. Thalheimer U, De Iorio F, Capra F., et al. Altered intestinal function precedes the appearance of bacterial DNA in serum and ascites in patients with cirrhosis: a pilot study. Eur J Gastroenterol Hepatol: 2010; 22 10 1228 1234
126. Kalaitzakis E, Johansson JE, Bjarnason I, Björnsson E. Intestinal permeability in cirrhotic patients with and without ascites. Scand J Gastroenterol: 2006; 41 3 326 330
127. Zuckerman MJ, Buchwald D, Watts MT. Intestinal permeability to 51Cr-EDTA in patients on chronic ambulatory peritoneal dialysis. Nephron: 1994; 68 3 408 409 (Pubitemid 24316493)
128. Pascual S, Such J, Esteban A., et al. Intestinal permeability is increased in patients with advanced cirrhosis. Hepatogastroenterology: 2003; 50 53 1482 1486 (Pubitemid 37186515)
129. Campillo B, Pernet P, Bories PN, Richardet JP, Devanlay M, Aussel C. Intestinal permeability in liver cirrhosis: relationship with severe septic complications. Eur J Gastroenterol Hepatol: 1999; 11 7 755 759 (Pubitemid 29349020)
130. Ruan P, Gong ZJ, Zhang QR. Changes of plasma D(-)-lactate, diamine oxidase and endotoxin in patients with liver cirrhosis. Hepatobiliary Pancreat Dis Int: 2004; 3 1 58 61 (Pubitemid 38256126)
131. Chang CS, Chen GH, Lien HC, Yeh HZ. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology: 1998; 28 5 1187 1190
132. Morencos FC, de las Heras Castao G, Martn Ramos L, Lpez Arias MJ, Ledesma F, Pons Romero F. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci: 1995; 40 6 1252 1256
133. Such J, Francs R, Muoz C., et al. Detection and identification of bacterial DNA in patients with cirrhosis and culture-negative, nonneutrocytic ascites. Hepatology: 2002; 36 1 135 141 (Pubitemid 34700770)
134. Such J, Muoz C, Zapater P, Prez-Mateo M. Bacterial DNA induces a proinflammatory immune response in patients with decompensated cirrhosis. Gut: 2005; 54 10 1500, author reply 1500 (Pubitemid 41375210)
135. Alexander C, Rietschel ET. Bacterial lipopolysaccharides and innate immunity. J Endotoxin Res: 2001; 7 3 167 202 (Pubitemid 32894573)
136. Hurley JC. Endotoxemia: methods of detection and clinical correlates. Clin Microbiol Rev: 1995; 8 2 268 292
137. Hoek JB. Endotoxin and alcoholic liver disease: tolerance and susceptibility. Hepatology: 1999; 29 5 1602 1604 (Pubitemid 29211067)
138. Marshall JC, Foster D, Vincent JL., et al. MEDIC study. Diagnostic and prognostic implications of endotoxemia in critical illness: results of the MEDIC study. J Infect Dis: 2004; 190 3 527 534 (Pubitemid 38982092)
139. McCuskey RS, Urbaschek R, Urbaschek B. The microcirculation during endotoxemia. Cardiovasc Res: 1996; 32 4 752 763 (Pubitemid 26332314)
140. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol: 1987; 4 1 8 14 (Pubitemid 17045538)
141. Fujimoto M, Uemura M, Nakatani Y., et al. Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res: 2000; 24 4, Suppl 48S 54S (Pubitemid 30246880)
142. Fukui H. Relation of endotoxin, endotoxin binding proteins and macrophages to severe alcoholic liver injury and multiple organ failure. Alcohol Clin Exp Res: 2005; 29 11, Suppl 172S 179S (Pubitemid 43194347)
143. Nakatani Y, Fukui H, Kitano H., et al. Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver: 2001; 21 1 64 70 (Pubitemid 32112022)
144. Enomoto N, Ikejima K, Bradford B., et al. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology: 1998; 115 2 443 451
145. Schenker S, Bay MK. Alcohol and endotoxin: another path to alcoholic liver injury? Alcohol Clin Exp Res: 1995; 19 5 1364 1366
146. Bauer TM, Schwacha H, Steinbrückner B., et al. Small intestinal bacterial overgrowth in human cirrhosis is associated with systemic endotoxemia. Am J Gastroenterol: 2002; 97 9 2364 2370
147. Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol: 2002; 8 6 961 965
148. Lin RS, Lee FY, Lee SD., et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol: 1995; 22 2 165 172
149. Fukui H, Tsujita S, Matsumoto M., et al. Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver: 1995; 15 2 104 109
150. Galbois A, Thabut D, Tazi KA., et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology: 2009; 49 1 175 184
151. Hoekstra M, Korporaal SJ, Li Z, Zhao Y, Van Eck M, Van Berkel TJ. Plasma lipoproteins are required for both basal and stress-induced adrenal glucocorticoid synthesis and protection against endotoxemia in mice. Am J Physiol Endocrinol Metab: 2010; 299 6 E1038 E1043
152. Tsai MH, Peng YS, Chen YC., et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J Hepatol: 2009; 50 5 906 915
153. Gioannini TL, Zhang D, Teghanemt A, Weiss JP. An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation. J Biol Chem: 2002; 277 49 47818 47825 (Pubitemid 36159308)
154. David SA, Balaram P, Mathan VI. Characterization of the interaction of lipid A and lipopolysaccharide with human serum albumin: implications for an endotoxin carrier function for albumin. J Endotoxin Res: 1995; 2 99 106
155. Jalan R, Schnurr K, Mookerjee RP., et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology: 2009; 50 2 555 564
156. Klammt S, Mitzner S, Stange J., et al. Albumin-binding function is reduced in patients with decompensated cirrhosis and correlates inversely with severity of liver disease assessed by model for end-stage liver disease. Eur J Gastroenterol Hepatol: 2007; 19 3 257 263
157. Oettl K, Stadlbauer V, Petter F., et al. Oxidative damage of albumin in advanced liver disease. Biochim Biophys Acta: 2008; 1782 7-8 469 473
158. Kouoh F, Gressier B, Luyckx M., et al. Antioxidant properties of albumin: effect on oxidative metabolism of human neutrophil granulocytes. Farmaco: 1999; 54 10 695 699 (Pubitemid 29494924)
159. Anraku M, Yamasaki K, Maruyama T, Kragh-Hansen U, Otagiri M. Effect of oxidative stress on the structure and function of human serum albumin. Pharm Res: 2001; 18 5 632 639 (Pubitemid 32595791)
160. Fernndez J, Monteagudo J, Bargallo X., et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology: 2005; 42 3 627 634 (Pubitemid 41233655)
161. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R.; SAFE Study Investigators. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med: 2004; 350 22 2247 2256 (Pubitemid 38669207)
162. Ballmer PE, Walshe D, McNurlan MA, Watson H, Brunt PW, Garlick PJ. Albumin synthesis rates in cirrhosis: correlation with Child-Turcotte classification. Hepatology: 1993; 18 2 292 297 (Pubitemid 23225098)
163. Barle H, Januszkiewicz A, Hllström L., et al. Albumin synthesis in humans increases immediately following the administration of endotoxin. Clin Sci (Lond): 2002; 103 5 525 531 (Pubitemid 35305638)
164. Wang XY, Li WQ, Lu J, Li N, Li JS. Lipopolysaccharide decreasing albumin expression in rat hepatocytes. Hepatobiliary Pancreat Dis Int: 2005; 4 3 410 415 (Pubitemid 41207545)
165. Wang XY, Li WQ, Lu J, Li N, Li JS. [Mechanism of reduction of albumin expression induced by lipopolysaccharide in rat hepatocytes]. Chin Med J (Engl): 2005; 118 20 1695 1702 (Pubitemid 41631678)
166. Ruot B, Bchereau F, Bayle G, Breuill D, Obled C. The response of liver albumin synthesis to infection in rats varies with the phase of the inflammatory process. Clin Sci (Lond): 2002; 102 1 107 114 (Pubitemid 34177807)
167. Hayashi T, Era S, Kawai K., et al. Observation for redox state of human serum and aqueous humor albumin from patients with senile cataract. Pathophysiology: 2000; 6 237 243 (Pubitemid 30050655)
168. Hughes WL, Dintzis HM. Crystallization of the mercury dimers of human and bovine mercaptalbumin. J Biol Chem: 1964; 239 845 849
169. Peters T. All About Albumin: Biochemistry, Genetics, and Medical Applications. San Diego, CA Academic: 1996
170. Oettl K, Stauber RE. Physiological and pathological changes in the redox state of human serum albumin critically influence its binding properties. Br J Pharmacol: 2007; 151 5 580 590 (Pubitemid 47016287)
171. El Kebir D, Jzsef L, Filep JG. Neutrophil recognition of bacterial DNA and Toll-like receptor 9-dependent and -independent regulation of neutrophil function. Arch Immunol Ther Exp (Warsz): 2008; 56 1 41 53 (Pubitemid 351651405)
172. Leifer CA, Kennedy MN, Mazzoni A, Lee C, Kruhlak MJ, Segal DM. TLR9 is localized in the endoplasmic reticulum prior to stimulation. J Immunol: 2004; 173 2 1179 1183 (Pubitemid 38924294)
173. Broad A, Jones DE, Kirby JA. Toll-like receptor (TLR) response tolerance: a key physiological "damage limitationo" effect and an important potential opportunity for therapy. Curr Med Chem: 2006; 13 21 2487 2502 (Pubitemid 44364151)
174. Latz E, Schoenemeyer A, Visintin A., et al. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol: 2004; 5 2 190 198 (Pubitemid 38208361)
175. Sabroe I, Prince LR, Jones EC., et al. Selective roles for Toll-like receptor (TLR)2 and TLR4 in the regulation of neutrophil activation and life span. J Immunol: 2003; 170 10 5268 5275 (Pubitemid 36554761)
176. Stadlbauer V, Mookerjee RP, Wright GA., et al. Role of Toll-like receptors 2, 4, and 9 in mediating neutrophil dysfunction in alcoholic hepatitis. Am J Physiol Gastrointest Liver Physiol: 2009; 296 1 G15 G22
177. Testro AG, Visvanathan K. Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol: 2009; 24 6 943 954
178. Testro AG, Gow PJ, Angus PW., et al. Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol: 2010; 52 2 199 205
179. Manigold T, Böcker U, Hanck C., et al. Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis. Eur J Gastroenterol Hepatol: 2003; 15 3 275 282 (Pubitemid 36337848)
180. Riordan SM, Skinner N, Nagree A., et al. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology: 2003; 37 5 1154 1164 (Pubitemid 36538693)
181. Francs R, Zapater P, Gonzlez-Navajas JM., et al. Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis. Hepatology: 2008; 47 3 978 985 (Pubitemid 351449689)
182. Castellote J, Girbau A, Maisterra S, Charhi N, Ballester R, Xiol X. Spontaneous bacterial peritonitis and bacterascites prevalence in asymptomatic cirrhotic outpatients undergoing large-volume paracentesis. J Gastroenterol Hepatol: 2008; 23 2 256 259 (Pubitemid 351257669)
183. Wong F, Bernardi M, Balk R., et al. International Ascites Club. Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut: 2005; 54 5 718 725 (Pubitemid 40559261)
184. Silvestre JP, Coelho LM, Pvoa PM. Impact of fulminant hepatic failure in C-reactive protein? J Crit Care: 2010; 25 4 657, e7-e12
185. Bota DP, Van Nuffelen M, Zakariah AN, Vincent JL. Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver. J Lab Clin Med: 2005; 146 6 347 351 (Pubitemid 41712021)
186. Elefsiniotis IS, Petrocheilou A, Scarmeas N., et al. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment. J Clin Virol: 2006; 37 4 329 331 (Pubitemid 44667675)
187. Vento S, Garofano T, Renzini C., et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med: 1998; 338 5 286 290 (Pubitemid 28065254)
188. Keeffe EB. Hepatitis A and B superimposed on chronic liver disease: vaccine-preventable diseases. Trans Am Clin Climatol Assoc: 2006; 117 227 237, discussion 237-238
189. Kumar M, Herrera JL. Importance of hepatitis vaccination in patients with chronic liver disease. South Med J: 2010; 103 12 1223 1231
190. Fiore AE, Uyeki TM, Broder K., et al. Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep: 2010; 59 RR-8 1 62
191. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23). MMWR Morb Mortal Wkly Rep: 2010; 59 34 1102 1106
192. Impfausschuss. Impfplan 2011 sterreich Evidenz-basierte Empfehlungen des Obersten Sanitätsrates. 12. October 2010
193. Chavez-Tapia NC, Barrientos-Gutierrez T, Tellez-Avila FI, Soares-Weiser K, Uribe M. Antibiotic prophylaxis for cirrhotic patients with upper gastrointestinal bleeding. Cochrane Database Syst Rev: 2010; 9 CD002907
194. Runyon BA.; AASLD Practice Guidelines Committee. Management of adult patients with ascites due to cirrhosis: an update. Hepatology: 2009; 49 6 2087 2107
195. Cohen MJ, Sahar T, Benenson S, Elinav E, Brezis M, Soares-Weiser K. Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding. Cochrane Database Syst Rev: 2009; 2 CD004791
196. European Association For The Study Of The Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol: 2009; 50 2 227 242
197. Lok AS, McMahon BJ.; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B: update of recommendations. Hepatology: 2004; 39 3 857 861 (Pubitemid 38337668)
198. Vilstrup H. Cirrhosis and bacterial infections. Rom J Gastroenterol: 2003; 12 4 297 302 (Pubitemid 38111866)
199. Nakamura I, Ochiai K, Imawari M. Phagocytic function of neutrophils of patients with decompensated liver cirrhosis is restored by oral supplementation of branched-chain amino acids. Hepatol Res: 2004; 29 4 207 211 (Pubitemid 39060773)
200. Abou-Assi SG, Mihas AA, Gavis EA., et al. Safety of an immune-enhancing nutrition supplement in cirrhotic patients with history of encephalopathy. JPEN J Parenter Enteral Nutr: 2006; 30 2 91 96 (Pubitemid 44314782)
201. Jarchum I, Pamer EG. Regulation of innate and adaptive immunity by the commensal microbiota. Curr Opin Immunol: 2011; 23 3 353 360
202. Fedorak RN. Understanding why probiotic therapies can be effective in treating IBD. J Clin Gastroenterol: 2008; 42 Suppl 3, Pt 1 S111 S115
203. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology: 2005; 41 3 422 433 (Pubitemid 40289486)
204. Riordan SM, Williams R. The intestinal flora and bacterial infection in cirrhosis. J Hepatol: 2006; 45 5 744 757 (Pubitemid 44466668)
205. An H, Xu H, Yu Y., et al. Up-regulation of TLR9 gene expression by LPS in mouse macrophages via activation of NF-kappaB, ERK and p38 MAPK signal pathways. Immunol Lett: 2002; 81 3 165 169 (Pubitemid 34310220)
206. Dbouk N, McGuire BM. Hepatic encephalopathy: a review of its pathophysiology and treatment. Curr Treat Options Gastroenterol: 2006; 9 6 464 474 (Pubitemid 44803668)
207. Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev: 2007; 1 CD005165
208. D'Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ: 2002; 324 7350 1361
209. Cremonini F, Di Caro S, Nista EC., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther: 2002; 16 8 1461 1467 (Pubitemid 34953587)
210. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol: 2006; 101 4 812 822
211. Isakow W, Morrow LE, Kollef MH. Probiotics for preventing and treating nosocomial infections: review of current evidence and recommendations. Chest: 2007; 132 1 286 294 (Pubitemid 47068233)
212. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol: 2008; 48 6 945 951
213. Lata J, Novotn I, Prbramsk V., et al. The effect of probiotics on gut flora, level of endotoxin and Child-Pugh score in cirrhotic patients: results of a double-blind randomized study. Eur J Gastroenterol Hepatol: 2007; 19 12 1111 1113 (Pubitemid 350125383)
214. Eguchi S, Takatsuki M, Hidaka M, Soyama A, Ichikawa T, Kanematsu T. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg: 2011; 201 4 498 502
215. Chavez-Tapia NC, Soares-Weiser K, Brezis M, Leibovici L. Antibiotics for spontaneous bacterial peritonitis in cirrhotic patients. Cochrane Database Syst Rev: 2009; 1 CD002232
216. Acevedo JG, Fernandez J, Castro M., et al. Current efficacy of recommended empirical antibiotic therapy in patients with cirrhosis and bacterial infection [abstract 6]. Opening and general session 1 2009;Apr 23,: 2009
217. Hassanein TI, Schade RR, Hepburn IS. Acute-on-chronic liver failure: extracorporeal liver assist devices. Curr Opin Crit Care: 2011; 17 2 195 203
218. Stadlbauer V, Krisper P, Aigner R., et al. Effect of extracorporeal liver support by MARS and Prometheus on serum cytokines in acute-on-chronic liver failure. Crit Care: 2006; 10 6 R169
219. Doria C, Marino IR. Bacteremia using the molecular adsorbent recirculating system in patients bridged to liver transplantation. Exp Clin Transplant: 2005; 3 1 289 292
220. Davies N, Proven A, Leckie P., et al. The development and testing of the UCL liver support device (UCL-ARSeNEL): improvement of survival in paracetamol-induced acute liver failure pigs [abstract]. Hepatology: 2010; 52 1616
221. Oettl K, Stadlbauer V, Krisper P, Stauber RE. Effect of extracorporeal liver support by molecular adsorbents recirculating system and Prometheus on redox state of albumin in acute-on-chronic liver failure. Ther Apher Dial: 2009; 13 5 431 436
222. Oettl K, Marsche G. Redox state of human serum albumin in terms of cysteine-34 in health and disease. Methods Enzymol: 2010; 474 181 195
223. Klammt S, Koball S, Hickstein H., et al. Increase of octanoate concentrations during extracorporeal albumin dialysis treatments. Ther Apher Dial: 2009; 13 5 437 443
224. Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF. Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis: 2010; 30 3 232 244
225. Rice TW, Wheeler AP, Bernard GR., et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis. Crit Care Med: 2010; 38 8 1685 1694
226. Tidswell M, Tillis W, Larosa SP., et al. Eritoran Sepsis Study Group. Phase 2 trial of eritoran tetrasodium (E5564), a toll-like receptor 4 antagonist, in patients with severe sepsis. Crit Care Med: 2010; 38 1 72 83